EP300 and hepatocellular carcinoma: Notably, the diabetes therapeutic metformin (Met) effectively disrupts these Twist1-YY1-p300 condensates, leading to significant downregulation of miR-9 expression and subsequent suppression of HCC malignancy (Meng et al., 2023).